DOCSLIB.ORG

Peripheral Vascular Disease and Hypertension: a Forgotten Association?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Peripheral Vascular Disease and Hypertension: a Forgotten Association? Journal of Human Hypertension (2001) 15, 447–454 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh REVIEW ARTICLE Peripheral vascular disease and hypertension: a forgotten association? A Makin1,2, GYH Lip1, S Silverman2 and DG Beevers1 1University Department of Medicine; 2Department of Vascular Surgery, City Hospital, Birmingham B18 7QH, UK Peripheral vascular disease (PVD) is associated with a ical associations, hypertension contributes to the high cardiovascular morbidity and mortality. Intermit- pathogenesis of atherosclerosis, the basic underlying tent claudication is the most common symptomatic pathological process underlying PVD. Hypertension, in manifestation of PVD, but is also an important predictor common with PVD, is associated with abnormalities of of cardiovascular death, increasing it by three-fold, and haemostasis and lipids, leading to an increased ather- increasing all-cause mortality by two to five-fold. Hyper- othrombotic state. Nevertheless, none of the large anti- tension is a common and important risk factor for vas- hypertensive treatment trials have adequately cular disorders, including PVD. Of hypertensives at addressed whether a reduction in blood pressure presentation, about 2–5% have intermittent claudi- causes a decrease in PVD incidence. There is therefore cation, with this prevalence increasing with age. Simi- an obvious need for such outcome studies, especially larly, 35–55% of patients with PVD at presentation also since the two conditions are commonly encountered have hypertension. Patients who suffer from hyperten- together. sion with PVD have a greatly increased risk of myocar- Journal of Human Hypertension (2001) 15, 447–454 dial infarction and stroke. Apart from the epidemiolog- Keywords: hypertension; peripheral vascular disease; atherosclerosis Introduction associations, hypertension also contributes to the pathogenesis of atherosclerosis, which is the basic Peripheral vascular disease (PVD) is the cause of a underlying pathological process underlying PVD.12– large number of hospitalisations each year. In the 14 Indeed, hypertension, in common with PVD, is United States of America, 9.6% of ‘cardiovascular also associated with abnormalities of haemostasis events’ are due to PVD, requiring 63 000 hospital 1 and the lipid profile. admissions every year. In addition, PVD is associa- Although it seems logical that the treatment of ted with a significant morbidity and mortality. In a hypertension should lead to a reduction in the inci- study in Finland, for example, patients with inter- dence of PVD, none of the large placebo-controlled mittent claudication had a three-fold excess risk of antihypertensive treatment trials have adequately death over 5 years from cardiovascular causes, when 2 addressed this question as a primary outcome meas- compared to men without claudication. This high ure. There is therefore an obvious need for more adverse outcome is also illustrated by an Israeli information on such outcomes especially since the study, where 44% of all men with intermittent two conditions are both common and closely claudication died within 21 years, when compared related. with 29% without PVD.3 Hypertension is a common and important risk fac- tor for all vascular disorders, including PVD.4,5 In Epidemiology of PVD hypertensive patients at presentation, between 2– 5% have intermittent claudication, with this preva- Intermittent claudication is the most common symp- lence increasing with age.6 Similarly, 35–55% of tomatic manifestation of PVD. Nevertheless these patients with PVD at presentation also have hyper- patients represent the tip of the iceberg as many tension.7–11 Apart from these epidemiological more patients have asymptomatic PVD (Table 1). The methods of case ascertainment with differing criteria for diagnosis and the diverse populations of Correspondence: Dr GYH Lip, E-mail: g.y.h.lipȰbham.ac.uk varying ages which have been studied may explain This paper was submitted to and dealt with by the USA Office of the Journal of Human Hypertension. the wide variation in the prevalence of PVD in the Received 1 February 2001; revised 6 February 2001; accepted 20 world literature. February 2001 In the Edinburgh Artery Study, which studied a Peripheral vascular disease and hypertension A Makin et al 448 Table 1 Examples of studies demonstrating the prevalence of intermittent claudication compared to peripheral vascular disease Country Reference No. Age IC PVD Edinburgh Fowkas et al82 1592 55–74 4.5% 26.2% Italy (ADEP) Violi et al11 613 (mean) 66 1.7% (f) 27.7% 2.2% (m) Sardinia Binaghi et al7 577 over 20 0.38% (f) 2.06% (f) 1.5% (m) 8.43% (m) Rotterdam Meijer et al17 4629 (f) over 55 1.2% (f) 20.5% (f) 3086 (m) 2.2% (m) 16.9% (m) Scandanavia Reunanan et al2 5224 (f) 30–59 1.8% (f) — 5738 (m) 2.1% (m) Israel Bowlin et al19 10059 (m) 40–65 2.7% (m) — Framingham USA Kannel et al28 19501 (f) 29–74 0.24% (f) — 15290 (m) 0.52% (m) f, female; m, male; IC, intermittent claudication; PVD, peripheral vascular disease (symptomatic and asymptomatic). population of 1592 subjects aged 55 to 74 years, predict disease progression in patients with estab- 4.6% had intermittent claudication but in addition, lished PVD.20 In the Quebec Cardiovascular Study, 6.6% had major asymptomatic PVD diagnosed clini- 4570 men between the ages of 35 and 64 were fol- cally and 15% had minor asymptomatic disease.4 In lowed up for 12 years. During this period, 188 a Sardinian population of people aged over 20 years, developed intermittent claudication for the first 4.7% had PVD, measured using a standard question- time, this being an annual incidence of 41/10 000 naire together with Doppler blood flow studies per year. Those developing intermittent claudi- although only 18.5% of these were symptomatic at cation were significantly more likely to have elev- the time of examination.7 ated blood pressure than the non-PVD examinees.21 Variable findings have been noted in other stud- The 38-year data from The Framingham Study ies. In an American study of 613 men and women, reported an increase in incidence of intermittent the prevalence of large vessel disease was 11.7%, claudication from 0.9% over 4 years in men aged small vessel disease 16% and combined large and 45–54 to 2.5% in men aged 65–75 until the 75 to small vessel involvement was present in 5.2% of 84-year-old cohort, where the incidence decreased participants.15 In a different study, the same authors to 1.9% over 4 years. Importantly, this change was reported that patients with severe PVD had signifi- very strongly correlated with the presence of Stage cantly elevated systolic blood pressure, although 2 (or higher) hypertension (systolic blood pressure they fail to define what the term ‘severe’ meant.16 In Ͼ160 mm Hg or diastolic blood pressure over 100).22 the Rotterdam Study of 7715 men and women aged over 55 years, PVD was present in 16.9% of men Hypertension as a contributor to PVD and 20.5% of women but symptomatic disease was only reported in 2.2% and 1.2% respectively;17 simi- Hypertension, and particularly the height of the sys- larly in Limburg, PVD was present in 8.6% of 3650 tolic blood pressure, is a well established risk factor subjects but was symptomatic in only 3.8%.18 In a for heart disease and stroke.4,5 As far back as 1962 Scandinavian sample of 10 962 aged 30–59 years, actuarial studies demonstrated that, as is now intermittent claudication was present in 2.1% of accepted, these complications are more closely asso- men and 1.8% of women2 and in 10 059 Israeli men ciated with the systolic rather than the diastolic aged 40–65 years, 2.7% responded positively when blood pressure elevation.23 In the Glasgow Blood asked about intermittent claudication symptoms.19 Pressure Clinic, it was even shown that there was One retrospective study of women from Belgium no relationship between change in diastolic blood showed that of 45 proven cases of PVD, 16 (36%) pressure and cardiovascular death.24 Whilst the had asymptomatic disease, whilst 19 (42%) had mortality from all causes is reduced by a reduction intermittent claudication and 10 (22%) had rest pain in systolic blood pressure, it remains 2–5 times and necrosis.12 higher than the mortality in the surrounding general Whilst there are much data on the prevalence of population,25 although there has been a recent trend PVD, few studies have specifically addressed the for the cardiovascular mortality in hypertensive incidence of PVD in large populations at follow up. patients to return to that of the population at The data from the TransAtlantic Inter-society large.26,27 Consensus (TASC) reveals that although hyperten- Follow-up data from the Framingham Study sion is a risk factor for development of PVD and is found a 2.5 to four-fold increased risk of PVD in men predictor of mortality in these patients it is not the and women with hypertension.5,28 In a post mortem most significant. Furthermore it does not seem to study of 1164 young men aged 15–34 years, 13.7% Journal of Human Hypertension Peripheral vascular disease and hypertension A Makin et al 449 had renal changes indicative of hypertension and approximately twice as common in hypertensive they had a higher prevalence of raised atheroscler- patients compared with normotensives. In addition otic lesions occupying Ͼ5% of the intimal area of the ADAM study discovered an odds ratio of about the abdominal aorta of between 1.3 and 1.6-fold, 1.2 of having an undiagnosed AAA in hypertensives compared to the normotensive group.29 In these compared to normotensives in a population of 50– patients, the prevalence of abdominal aortic raised 79 year olds.32 This data also shows a much lower lesions was greater than that of raised lesions in the prevalence of AAA (defined as an abdominal aorta right coronary artery, which was somewhat unex- greater than 4.0 cm in diameter) in this age group pected, as hypertension is usually perceived as a (1.4%) than the other studies.
Load more

Recommended publications
  • Cardiac Imaging Guidelines Effective October 1, 2021
    Cigna Medical Coverage Policies – Radiology Cardiac Imaging Guidelines Effective October 1, 2021 ____________________________________________________________________________________ Instructions for use The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer’s particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of: 1. The terms of the applicable benefit plan document in effect on the date of service 2. Any applicable laws and regulations 3. Any relevant collateral source materials including coverage policies 4. The specific facts of the particular situation Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines. This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policyy m na ot apply to all benefit plans administered by Cigna. These guidelines include procedures eviCore does not review for Cigna.
    [Show full text]
  • Control Study of Pregnancy Complications and Birth Outcomes
    Hypertension Research (2011) 34, 55–61 & 2011 The Japanese Society of Hypertension All rights reserved 0916-9636/11 $32.00 www.nature.com/hr ORIGINAL ARTICLE Hypotension in pregnant women: a population-based case–control study of pregnancy complications and birth outcomes Ferenc Ba´nhidy1,Na´ndor A´ cs1, Erzse´bet H Puho´ 2 and Andrew E Czeizel2 Hypotension is frequent in pregnant women; nevertheless, its association with pregnancy complications and birth outcomes has not been investigated. Thus, the aim of this study was to analyze the possible association of hypotension in pregnant women with pregnancy complications and with the risk for preterm birth, low birthweight and different congenital abnormalities (CAs) in the children of these mothers in the population-based data set of the Hungarian Case–Control Surveillance of CAs, 1980–1996. Prospectively and medically recorded hypotension was evaluated in 537 pregnant women who later had offspring with CAs (case group) and 1268 pregnant women with hypotension who later delivered newborn infants without CAs (control group); controls were matched to sex and birth week of cases (in the year when cases were born), in addition to residence of mothers. Over half of the pregnant women who had chronic hypotension were treated with pholedrine or ephedrine. Maternal hypotension is protective against preeclampsia; however, hypotensive pregnant women were at higher risk for severe nausea or vomiting, threatened abortion (hemorrhage in early pregnancy) and for anemia. There was no clinically important difference in the rate of preterm births and low birthweight newborns in pregnant women with or without hypotension. The comparison of the rate of maternal hypotension in cases with 23 different CAs and their matched controls did not show a higher risk for CAs (adjusted OR with 95% confidence intervals: 0.66, 0.49–0.84).
    [Show full text]
  • National Taiwan University Hospital Hsinchu Branch Research Protocol 2018
    National Taiwan University Hospital Hsinchu Branch Research Protocol 2018 1. Project name Prevalence and Outcomes of Peripheral Artery Disease in Sepsis Patients in the Medical Title Intensive Care Unit Principal Department of Internal Medicine, Cardiovascular Division investigator Mu-Yang Hsieh, Attending Physician Table of Contents 1. Project name.........................................................................................................................................................1 2. Abstract................................................................................................................................................................3 Background...............................................................................................................................................................3 Methods....................................................................................................................................................................3 3. Background..........................................................................................................................................................4 Prior research in this field.........................................................................................................................................4 Sepsis and peripheral artery disease..............................................................................................................4 Peripheral artery disease- its impact on the outcomes..................................................................................4
    [Show full text]
  • Vasculitis: Pearls for Early Diagnosis and Treatment of Giant Cell Arteritis
    Vasculitis: Pearls for early diagnosis and treatment of Giant Cell Arteritis Mary Beth Humphrey, MD, PhD Professor of Medicine McEldowney Chair of Immunology [email protected] Office Phone: 405 271-8001 ext 35290 October 2019 Relevant Disclosure and Resolution Under Accreditation Council for Continuing Medical Education guidelines disclosure must be made regarding relevant financial relationships with commercial interests within the last 12 months. Mary Beth Humphrey I have no relevant financial relationships or affiliations with commercial interests to disclose. Experimental or Off-Label Drug/Therapy/Device Disclosure I will be discussing experimental or off-label drugs, therapies and/or devices that have not been approved by the FDA. Objectives • To recognize early signs of vasculitis. • To discuss Tocilizumab (IL-6 inhibitor) as a new treatment option for temporal arteritis. • To recognize complications of vasculitis and therapies. Professional Practice Gap Gap 1: Application of imaging recommendations in large vessel vasculitis Gap 2: Application of tocilizimab in treatment of giant cell vasculitis Cranial Symptoms Aortic Vision loss Aneurysm GCA Arm PMR Claudication FUO Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Giant Cell Arteritis • Most common form of systemic vasculitis in adults – Incidence: ~ 1/5,000 persons > 50 yrs/year – Lifetime risk: 1.0% (F) 0.5% (M) • Cause: unknown At risk: Women (80%) > men (20%) Northern European ancestry>>>AA>Hispanics Age: average age at onset ~73 years Smoking: 6x increased risk Kermani TA, et al Ann Rheum Dis.
    [Show full text]
  • Jordan M. Garrison, Md Facs Fasmbs What Are We Talking About?
    PERIPHERAL VASCULAR DISEASE JORDAN M. GARRISON, MD FACS FASMBS WHAT ARE WE TALKING ABOUT? Peripheral Arterial Disease (PAD) • Near or Complete obstruction of > 1 Peripheral Artery Peripheral Venous Reflux Disease • Varicose Veins • Chronic Venous Stasis Ulcer Disease • Phlegmasia Cerulia Dolans or Alba Dolans (Milk Leg) • Deep Vein Thrombosis and Pulmonary Embolus Disease Coronary Artery Disease ◦ Myocardial Infarct Aneurysmal Disease • Aortic • Popliteal Cerebral and Carotid Artery Disease • Stroke • TIA Renal Vascular Hypertensive Disease • High Blood Pressure • Kidney Failure Peripheral Arterial Disease PREVELANCE Males > Females 10% of People over 60 Race • AA double the rate of all other ethnicities High Income Countries Peripheral Arterial Disease RISK FACTORS Smoking is the #1 risk factor Diabetes Mellitus Diet Obesity ETOH Cholesterol Heredity Lifestyle Homocysteine, C Reactive Protein, Fibrinogen Arterial Anatomy Lower Extremity Anatomy Plaque Formation Plaque Peripheral Arterial Disease Claudication • Disabling • Intestinal Limb Threatening Ischemia(LTI) Critical Limb Ischemia(CLI) • Rest Pain • Tissue Loss • Gangrene Disabling Claudication Intestinal Ischemia Intestinal Claudication Peripheral Arterial Disease Claudication • Disabling • Intestinal Limb Threatening Ischemia(LTI) Critical Limb Ischemia(CLI) • Rest Pain • Tissue Loss • Gangrene Rest Pain/ Dependent Rubor Tissue Loss Gangrene Peripheral Artery Disease Diagnosis Segmental Pressures • Lower extremity Blood Pressures ABI • Nl >1.0, Diabetes will give elevated reading
    [Show full text]
  • Definitions • Septic Shock
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis Definitions • Septic shock: Persisting hypotension despite volume resuscitation, requiring vasopressors to maintain mean artery pressure (MAP) ≥65 mmHg and serum lactate level >2 mmol/L (1). • Renal failure: Doubling of basal Creatinine value or urine output <0.5 ml/kg/h for ≥12h (2) • Heart failure: Gradual or rapid change in heart failure signs and symptoms resulting in a need for urgent therapy (3). • Myocarditis: Myocarditis was diagnosed if serum levels of high-sensitivity cardiac troponin I were above the 99th percentile upper reference limit and compatible abnormalities were shown in electrocardiography and echocardiography. • Encephalopathy: Impaired consciousness as change of consciousness level (somnolence, stupor, and coma) or consciousness content (confusion and delirium) (4). • Thrombosis: Clinically or by imaging diagnosed acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism (5). References 1. World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection- when-novel-coronavirus-(ncov)-infection-is-suspected. 2. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179-84. 10.1159/000339789. 3. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958-3968. 4. Mao L, Jin H, Wang M, et al.
    [Show full text]
  • Hypertension: Putting the Pressure on the Silent Killer
    HYPERTENSION: PUTTING THE PRESSURE ON THE SILENT KILLER MAY 2016 TABLEHypertension: putting OF the CONTENTS pressure on the silent killer Table of contents UNDERSTANDING HYPERTENSION AND THE LINK TO CARDIOVASCULAR DISEASE 2 Understanding hypertension and the link to cardiovascular disease THEThe social SOCIAL and economic AND impact ECONOMIC of hypertension IMPACT OF HYPERTENSION 3 Diagnosing and treating hypertension – what is out there? DIAGNOSINGChallenges to tackling hypertension AND TREATING HYPERTENSION – WHAT IS OUT THERE? 6 Opportunities and focus areas for policymakers CHALLENGES TO TACKLING HYPERTENSION 9 OPPORTUNITIES AND FOCUS AREAS FOR POLICYMAKERS 15 HYPERTENSION: PUTTING THE PRESSURE ON THE SILENT KILLER UNDERSTANDING HYPERTENSION AND THE LINK TO CARDIOVASCULAR DISEASE Cardiovascular disease (CVD), or heart disease, is the number one cause of death in the world. 80% of deaths due to CVD occur in countries and poor communities where health systems are weak, and CVD accounts for nearly half of the estimated US$500 billion annual lost economic output associated with noncommunicable diseases (NCDs) in low-income and middle-income countries. In 2012, CVD killed 17.5 million people – the equivalent of every 3 in 10 deaths.1 Of these 17 million deaths a year, over half – 9.4 million - are caused by complications in hypertension, also commonly referred to as raised or high blood pressure2. Hypertension is a risk factor for coronary heart disease and the single most important risk factor for stroke - it is responsible for at least 45% of deaths due to heart disease, and at least 51% of deaths due to stroke. High blood pressure is defined as a systolic blood pressure at or above 140 mmHg and/or a diastolic blood pressure at or above 90 mmHg.
    [Show full text]
  • Hypertension and Coronary Heart Disease
    Journal of Human Hypertension (2002) 16 (Suppl 1), S61–S63 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Hypertension and coronary heart disease E Escobar University of Chile, Santiago, Chile The association of hypertension and coronary heart atherosclerosis, damage of arterial territories other than disease is a frequent one. There are several patho- the coronary one, and of the extension and severity of physiologic mechanisms which link both diseases. coronary artery involvement. It is important to empha- Hypertension induces endothelial dysfunction, exacer- sise that complications and mortality of patients suffer- bates the atherosclerotic process and it contributes to ing a myocardial infarction are greater in hypertensive make the atherosclerotic plaque more unstable. Left patients. Treatment should be aimed to achieve optimal ventricular hypertrophy, which is the usual complication values of blood pressure, and all the strategies to treat of hypertension, promotes a decrease of ‘coronary coronary heart disease should be considered on an indi- reserve’ and increases myocardial oxygen demand, vidual basis. both mechanisms contributing to myocardial ischaemia. Journal of Human Hypertension (2002) 16 (Suppl 1), S61– From a clinical point of view hypertensive patients S63. DOI: 10.1038/sj/jhh/1001345 should have a complete evaluation of risk factors for Keywords: hypertension; hypertrophy; coronary heart disease There is a strong and frequent association between arterial hypertension.8 Hypertension is frequently arterial hypertension and coronary heart disease associated to metabolic disorders, such as insulin (CHD). In the PROCAM study, in men between 40 resistance with hyperinsulinaemia and dyslipidae- and 66 years of age, the prevalence of hypertension mia, which are additional risk factors of atheroscler- in patients who had a myocardial infarction was osis.9 14/1000 men in a follow-up of 4 years.
    [Show full text]
  • Orthostatic Hypotension in a Cohort of Hypertensive Patients Referring to a Hypertension Clinic
    Journal of Human Hypertension (2015) 29, 599–603 © 2015 Macmillan Publishers Limited All rights reserved 0950-9240/15 www.nature.com/jhh ORIGINAL ARTICLE Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic C Di Stefano, V Milazzo, S Totaro, G Sobrero, A Ravera, A Milan, S Maule and F Veglio The prevalence of orthostatic hypotension (OH) in hypertensive patients ranges from 3 to 26%. Drugs are a common cause of non-neurogenic OH. In the present study, we retrospectively evaluated the medical records of 9242 patients with essential hypertension referred to our Hypertension Unit. We analysed data on supine and standing blood pressure values, age, sex, severity of hypertension and therapeutic associations of drugs, commonly used in the treatment of hypertension. OH was present in 957 patients (10.4%). Drug combinations including α-blockers, centrally acting drugs, non-dihydropyridine calcium-channel blockers and diuretics were associated with OH. These pharmacological associations must be administered with caution, especially in hypertensive patients at high risk of OH (elderly or with severe and uncontrolled hypertension). Angiotensin-receptor blocker (ARB) seems to be not related with OH and may have a potential protective effect on the development of OH. Journal of Human Hypertension (2015) 29, 599–603; doi:10.1038/jhh.2014.130; published online 29 January 2015 INTRODUCTION stabilization, and then at 1 and 3 min after standing. The average of the Orthostatic hypotension (OH) is defined as the reduction in blood last two SBP and DBP values measured in the supine position and the pressure (BP) of at least 20 mmHg systolic and/or 10 mm Hg lowest value during standing were considered.
    [Show full text]
  • Hypertension and the Prothrombotic State
    Journal of Human Hypertension (2000) 14, 687–690 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Hypertension and the prothrombotic state GYH Lip Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK The basic underlying pathophysiological processes related to conventional risk factors, target organ dam- underlying the major complications of hypertension age, complications and long-term prognosis, as well as (that is, heart attacks and strokes) are thrombogenesis different antihypertensive treatments. Further work is and atherogenesis. Indeed, despite the blood vessels needed to examine the mechanisms leading to this being exposed to high pressures in hypertension, the phenomenon, the potential prognostic and treatment complications of hypertension are paradoxically throm- implications, and the possible value of measuring these botic in nature rather than haemorrhagic. The evidence parameters in routine clinical practice. suggests that hypertension appears to confer a Journal of Human Hypertension (2000) 14, 687–690 prothrombotic or hypercoagulable state, which can be Keywords: hypercoagulable; prothrombotic; coagulation; haemorheology; prognosis Introduction Indeed, patients with hypertension are well-recog- nised to demonstrate abnormalities of each of these Hypertension is well-recognised to be an important 1 components of Virchow’s triad, leading to a contributor to heart attacks and stroke. Further- prothrombotic or hypercoagulable state.4 Further- more, effective antihypertensive therapy reduces more, the processes of thrombogenesis and athero- strokes by 30–40%, and coronary artery disease by 2 genesis are intimately related, and many of the basic approximately 25%. Nevertheless the basic under- concepts thrombogenesis can be applied to athero- lying pathophysiological processes underlying both genesis.
    [Show full text]
  • Guideline-Management-Giant-Cell
    Arthritis Care & Research Vol. 73, No. 8, August 2021, pp 1071–1087 DOI 10.1002/acr.24632 © 2021 American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis Mehrdad Maz,1 Sharon A. Chung,2 Andy Abril,3 Carol A. Langford,4 Mark Gorelik,5 Gordon Guyatt,6 Amy M. Archer,7 Doyt L. Conn,8 Kathy A. Full,9 Peter C. Grayson,10 Maria F. Ibarra,11 Lisa F. Imundo,5 Susan Kim,2 Peter A. Merkel,12 Rennie L. Rhee,12 Philip Seo,13 John H. Stone,14 Sangeeta Sule,15 Robert P. Sundel,16 Omar I. Vitobaldi,17 Ann Warner,18 Kevin Byram,19 Anisha B. Dua,7 Nedaa Husainat,20 Karen E. James,21 Mohamad A. Kalot,22 Yih Chang Lin,23 Jason M. Springer,1 Marat Turgunbaev,24 Alexandra Villa-Forte, 4 Amy S. Turner,24 and Reem A. Mustafa25 Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particu- lar patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome.
    [Show full text]
  • Risk Factors in Abdominal Aortic Aneurysm and Aortoiliac Occlusive
    OPEN Risk factors in abdominal aortic SUBJECT AREAS: aneurysm and aortoiliac occlusive PHYSICAL EXAMINATION RISK FACTORS disease and differences between them in AORTIC DISEASES LIFESTYLE MODIFICATION the Polish population Joanna Miko ajczyk-Stecyna1, Aleksandra Korcz1, Marcin Gabriel2, Katarzyna Pawlaczyk3, Received Grzegorz Oszkinis2 & Ryszard S omski1,4 1 November 2013 Accepted 1Institute of Human Genetics, Polish Academy of Sciences, Poznan, 60-479, Poland, 2Department of Vascular Surgery, Poznan 18 November 2013 University of Medical Sciences, Poznan, 61-848, Poland, 3Department of Hypertension, Internal Medicine, and Vascular Diseases, Poznan University of Medical Sciences, Poznan, 61-848, Poland, 4Department of Biochemistry and Biotechnology of the Poznan Published University of Life Sciences, Poznan, 60-632, Poland. 18 December 2013 Abdominal aortic aneurysm (AAA) and aortoiliac occlusive disease (AIOD) are multifactorial vascular Correspondence and disorders caused by complex genetic and environmental factors. The purpose of this study was to define risk factors of AAA and AIOD in the Polish population and indicate differences between diseases. requests for materials should be addressed to J.M.-S. he total of 324 patients affected by AAA and 328 patients affected by AIOD was included. Previously (joannastecyna@wp. published population groups were treated as references. AAA and AIOD risk factors among the Polish pl) T population comprised: male gender, advanced age, myocardial infarction, diabetes type II and tobacco smoking. This study allowed defining risk factors of AAA and AIOD in the Polish population and could help to develop diagnosis and prevention. Characteristics of AAA and AIOD subjects carried out according to clinical data described studied disorders as separate diseases in spite of shearing common localization and some risk factors.
    [Show full text]